Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFU58V)

Drug Name
AG2034 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
135465775
CAS Number
CAS 177575-17-6
TTD Drug ID
DMFU58V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting GAR transformylase (GART)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DDATHF DM6GWAC Discovery agent N.A. Investigative [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GAR transformylase (GART) TTCSJBZ PUR2_HUMAN Modulator [1]

References

1 Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
2 Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,... Biochemistry. 2003 May 27;42(20):6043-56.